医薬品研究開発アウトソーシングの世界市場：注目の洞察（2024年～2029年）

世界の医薬品研究開発アウトソーシングの市場規模は、2023年から2029年にかけて10.15%のCAGRで拡大すると予測されます。

2024年、Boehringer Ingelheimは、がんに対する革新的なチェックポイント阻害剤を開発するため、Nerio Therapeuticsから前臨床資産を取得し、最大13億米ドルの取引で、がん領域のポートフォリオを拡大しました。また、Ochre Bioと提携し、肝再生治療薬や慢性肝疾患の新規治療薬を開発します。2024年、AbbVieは中枢神経系（CNS）疾患の治療に特化したバイオテクノロジー企業であるAliadaを買収する最終合意を発表しました。Aliadaの革新的な血液脳関門（BBB）通過技術は、中枢神経系治療のブレークスルーをもたらす可能性があります。2024年、MerckはDNA直接修飾技術別がん治療薬を専門とするModifi Biosciences Inc.を買収しました。

細胞・遺伝子治療業界におけるアウトソーシングは、需要の増加、技術の複雑化、専門知識の必要性などを背景に、急速な成長を遂げています。開発・製造受託機関（CDMO）は、小規模なバイオテクノロジー企業や大手製薬会社でさえも、社内で対応するのに高額なコストをかけることなく、効率的に事業を拡大する上で極めて重要な役割を果たしています。専門施設の建設には1平方フィート当たり2,000ドルもの費用がかかり、完成までに数年かかることもあるため、アウトソーシングはコストと時間の両面で効率的な魅力的な選択肢となっています。このアウトソーシング・ブームの主な原動力は、業界の複雑さと、ウイルスベクター生産や遺伝子編集などの製造工程の高度に専門化した性質です。これらの業務をCDMOに委託することで、厳格な規制基準の遵守と高品質の成果が保証されます。例えば、Catalent、Lonza、Thermo Fisher Scientificなどの企業は、ウイルスベクター製造の専門知識を持つ中小企業の買収に多額の投資を行い、この新興市場での能力を拡大しています。

仮想・分散型臨床試験（DCT）は、遠隔医療、ウェアラブル、遠隔モニタリングなどの技術を活用し、自宅や地域の環境から患者の参加を可能にすることで、臨床調査に変革をもたらしつつあります。このアプローチは移動を減らし、アクセスを向上させ、COVID-19パンデミックの際に勢いを増しました。DCTは、地理的障壁を克服し、多様な参加を可能にし、コストを削減することで、患者の採用と維持を改善します。ウェアラブルによる継続的なデータ収集は、リアルタイムのモニタリングを強化し、正確性と安全性を向上させます。PfizerやNovartisのような大手企業は、FDAやEMAのような規制当局の支援を受けてDCTを採用しています。AI、e-consentシステム、ブロックチェーンベースのセキュリティの進歩により、DCTはよりスケーラブルで信頼性の高いものとなっており、ICON PlcやMedableのような企業が包括的なソリューションで主要企業となっています。しかし、データプライバシー、技術格差、患者のデジタルリテラシーといった課題は依然として残っています。バーチャルと従来の臨床試験の要素を組み合わせたハイブリッドモデルが、実行可能なソリューションとして台頭してきています。これらの障壁に対処することで、DCTは臨床研究のアクセシビリティ、効率性、革新性を促進すると期待されます。

当レポートでは、世界の医薬品研究開発アウトソーシング市場について調査し、市場の概要とともに、開発段階別、製品タイプ別、企業規模別、治療領域別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 医薬品研究開発アウトソーシング市場概要

• エグゼクティブサマリー
• 主な調査結果

第2章 医薬品研究開発アウトソーシング市場

• 世界：医薬品研究開発アウトソーシング市場の予測収益（2020年～2029年、10億米ドル）

第3章 医薬品研究開発アウトソーシング市場の見通しと機会

• 医薬品研究開発アウトソーシング市場の機会と動向
• 医薬品研究開発アウトソーシング市場の促進要因
• 医薬品研究開発アウトソーシング市場の抑制要因

第4章 医薬品研究開発アウトソーシング市場セグメンテーションデータ

• 世界：開発段階別の予想収益（2020年～2029年、10億米ドル）
• 世界：製品タイプ別の予想収益（2020年～2029年、10億米ドル）
• 世界：企業規模別の予想収益（2020年～2029年、10億米ドル）
• 世界：治療領域別の予測収益（2020年～2029年、10億米ドル）

第5章 主要地域の概要

• 北米：医薬品研究開発アウトソーシング市場の予測収益（2020年～2029年、10億米ドル）
  • 米国
  • カナダ
• 欧州：医薬品研究開発アウトソーシング市場の予測収益（2020年～2029年、10億米ドル）
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
• アジア太平洋：医薬品研究開発アウトソーシング市場の予測収益（2020年～2029年、10億米ドル）
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
• ラテンアメリカ：医薬品研究開発アウトソーシング市場の予測収益（2020年～2029年、10億米ドル）
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ：医薬品研究開発アウトソーシング市場の予測収益（2020年～2029年、10億米ドル）
  • トルコ
  • サウジアラビア
  • 南アフリカ
  • UAE

第6章 医薬品研究開発アウトソーシング市場業界の概要

• 医薬品研究開発アウトソーシング市場-競合情勢
• 医薬品研究開発アウトソーシング市場- 主要ベンダーのプロファイル
• 医薬品研究開発アウトソーシング市場- その他の主要ベンダー
• 医薬品研究開発アウトソーシング市場- 主要な戦略的推奨事項

第7章 付録

LIST OF EXHIBITS

• Exhibit 1: Market Size & Forecast - Global Pharmaceutical R&D Outsourcing Market (2020-2029, $ BN)
• Exhibit 2: Market Size & Forecast - Clinical (2020-2029, $ BN)
• Exhibit 3: Market Size & Forecast - Non-clinical (2020-2029, $ BN)
• Exhibit 4: Market Size & Forecast - Small Molecules (2020-2029, $ BN)
• Exhibit 5: Market Size & Forecast -Biologics (2020-2029, $ BN)
• Exhibit 6: Market Size & Forecast - Small & Mid-Sized Companies (2020-2029, $ BN)
• Exhibit 7: Market Size & Forecast - Large Companies (2020-2029, $ BN)
• Exhibit 8: Market Size & Forecast - Oncology (2020-2029, $ BN)
• Exhibit 9: Market Size & Forecast - Cardiovascular Diseases (2020-2029, $ BN)
• Exhibit 10: Market Size & Forecast - Infectious Diseases (2020-2029, $ BN)
• Exhibit 11: Market Size & Forecast - Musculoskeletal Disorders (2020-2029, $ BN)
• Exhibit 12: Market Size & Forecast - Central Nervous System Disorders (2020-2029, $ BN)
• Exhibit 13: Market Size & Forecast - Gastrointestinal Disorders (2020-2029, $ BN)
• Exhibit 14: Market Size & Forecast - Others (2020-2029, $ BN)
• Exhibit 15: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in N. America (2020-2029, $ BN)
• Exhibit 16: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in the US (2020-2029, $ BN)
• Exhibit 17: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Canada (2020-2029, $ BN)
• Exhibit 18: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Europe (2020-2029, $ BN)
• Exhibit 19: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Germany (2020-2029, $ BN)
• Exhibit 20: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in UK (2020-2029, $ BN)
• Exhibit 21: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in France (2020-2029, $ BN)
• Exhibit 22: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Spain (2020-2029, $ BN)
• Exhibit 22: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Italy (2020-2029, $ BN)
• Exhibit 23: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in APAC (2020-2029, $ BN)
• Exhibit 24: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in China (2020-2029, $ BN)
• Exhibit 25: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Japan (2020-2029, $ BN)
• Exhibit 26: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in India (2020-2029, $ BN)
• Exhibit 27: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Australia (2020-2029, $ BN)
• Exhibit 28: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in S. Korea (2020-2029, $ BN)
• Exhibit 29: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in L. America (2020-2029, $ BN)
• Exhibit 30: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Mexico (2020-2029, $ BN)
• Exhibit 31: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Brazil (2020-2029, $ BN)
• Exhibit 32: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Argentina (2020-2029, $ BN)
• Exhibit 33: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in the MEA (2020-2029, $ BN)
• Exhibit 34: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Turkey (2020-2029, $ BN)
• Exhibit 35: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in S. Africa (2020-2029, $ BN)
• Exhibit 36: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in Saudi Arabia (2020-2029, $ BN)
• Exhibit 37: Market Size & Forecast - Pharmaceutical R&D Outsourcing Market in UAE (2020-2029, $ BN)

LIST OF TABLES

• Table 1: Global Pharmaceutical R&D Outsourcing Market (2020-2029, $ BN)
• Table 2: Global Pharmaceutical R&D Outsourcing Market by Stage of Development (2020-2029, %)
• Table 3: Global Pharmaceutical R&D Outsourcing Market by Stage of Development (2020-2029, $ BN)
• Table 4: Global Pharmaceutical R&D Outsourcing Market by Product Type (2020-2029, %)
• Table 5: Global Pharmaceutical R&D Outsourcing Market by Product Type (2020-2029, $ BN)
• Table 6: Global Pharmaceutical R&D Outsourcing Market by Company Size (2020-2029, %)
• Table 7: Global Pharmaceutical R&D Outsourcing Market by Company Size (2020-2029, $ BN)
• Table 8: Global Pharmaceutical R&D Outsourcing Market by Therapy Area (2020-2029, %)
• Table 9: Global Pharmaceutical R&D Outsourcing Market by Therapy Area (2020-2029, $ BN)
• Table 10: Global Pharmaceutical R&D Outsourcing Market by Geography (2020-2029, %)
• Table 11: Global Pharmaceutical R&D Outsourcing Market by Geography (2020-2029, $ BN)

The global pharmaceutical R&D outsourcing market is expected to grow at a CAGR of 10.15% from 2023 to 2029.

RECENT VENDORS ACTIVITIES

• In 2024, Boehringer Ingelheim expanded its oncology portfolio by acquiring preclinical assets from Nerio Therapeutics to develop innovative checkpoint inhibitors for cancer, in a deal worth up to USD 1.3 billion.
• The company also partnered with Ochre Bio to advance liver regeneration treatments and novel therapies for chronic liver diseases, with the collaboration valued at over USD 1 billion.
• In 2024, AbbVie announced a definitive agreement to acquire Aliada, a biotechnology company specializing in therapies for central nervous system (CNS) diseases. Aliada's innovative blood-brain barrier (BBB)-crossing technology is at the core of its approach, offering potential breakthroughs in CNS treatment.
• In 2024, Merck acquired Modifi Biosciences Inc., a company specializing in cancer therapeutics driven by direct DNA modification technology.

KEY TAKEAWAYS

• By Stage of Development: The clinical segment holds the largest market share. Clinical trials are a critical phase in drug development, and outsourcing these trials to specialized (CROs) helps streamline the process and manage costs effectively.
• By Product Type: The biologics segment shows the highest growth of 11.14%, as biologics complex therapies derived from living organisms are a major focus in pharmaceutical research and development.
• By Company Size: The small & mid-sized companies segment holds the largest market share. They also tend to focus on specialized therapeutic areas, which can make them attractive partners for outsourcing projects that require specialized expertise.
• By Therapy Area: The oncology segment holds the largest market share of over 30%. The segmental growth is due to the high demand for innovative cancer treatments and the need for efficient clinical trials.
• By Geography: APAC shows the highest growth of 11.91% in the global pharmaceutical R&D outsourcing market. The growth in this region is due to driven by a combination of cost efficiency, specialized expertise, and supportive government policies.
• Growth Factor: The global pharmaceutical R&D outsourcing market is set to grow due to the rise of platform trials in modern clinical research and the rise in patient-centric clinical trial approaches.

MARKET OPPORTUNITIES & DRIVERS

Outsourcing In The Cell And Gene Therapy Industry Is Booming

Outsourcing in the cell and gene therapy industry is experiencing rapid growth, driven by increasing demand, technological complexities, and the need for specialized expertise. Contract Development and Manufacturing Organizations (CDMOs) play a pivotal role in enabling small biotech firms and even large pharmaceutical companies to scale their operations effectively without incurring the prohibitive costs associated with in-house capabilities. Building specialized facilities can cost up to $2,000 per square foot and take several years to complete, making outsourcing an attractive alternative for both cost and time efficiency. Key drivers of this outsourcing boom include the industry's complexity and the highly specialized nature of manufacturing processes such as viral vector production and gene editing. Outsourcing these operations to CDMOs ensures adherence to stringent regulatory standards and high-quality outcomes. For instance, companies like Catalent, Lonza, and Thermo Fisher Scientific have made significant investments in acquiring smaller firms with expertise in viral vector production, expanding their capabilities in this emerging market.

Virtual & Decentralized Clinical Trials (DCTs) Gaining Momentum

Virtual and decentralized clinical trials (DCTs) are transforming clinical research by using technologies like telemedicine, wearables, and remote monitoring to enable patient participation from home or local settings. This approach reduces travel, enhances accessibility, and gained momentum during the COVID-19 pandemic. DCTs improve patient recruitment and retention by overcoming geographic barriers, enabling diverse participation, and reducing costs. Continuous data collection via wearables enhances real-time monitoring, improving accuracy and safety. Major companies like Pfizer and Novartis are adopting DCTs, supported by regulatory agencies like the FDA and EMA, which have guided digital tools. Advancements in AI, e-consent systems, and blockchain-based security are making DCTs more scalable and reliable, with companies like ICON Plc and Medable leading in comprehensive solutions. However, challenges such as data privacy, technological disparities, and patient digital literacy remain. Hybrid models that combine virtual and traditional trial elements are emerging as viable solutions. As these barriers are addressed, DCTs are expected to drive accessibility, efficiency, and innovation in clinical research.

Increasing Complexity of Drug Development

The increasing complexity of drug development, particularly with biologics, gene therapies, and personalized medicines, is driving the growth of pharmaceutical R&D outsourcing. These advanced therapies involve intricate processes like protein engineering and complex manufacturing, which require specialized expertise and cutting-edge technologies. Pharmaceutical companies are turning to Contract Research Organizations (CROs) to handle these tasks more efficiently and cost-effectively. Additionally, the demanding regulatory landscape, with agencies like the FDA and EMA imposing stricter requirements, has made outsourcing essential. CROs with regulatory expertise help ensure compliance, mitigate risks, and accelerate drug development timelines. Beyond formulation challenges, patient recruitment for clinical trials has become increasingly difficult, requiring diverse and representative populations. Outsourcing partners are using technology and big data to streamline recruitment, manage trial data efficiently, and ensure smooth trial execution. This combination of technical and regulatory expertise positions CROs as critical partners in navigating the complexities of modern drug development.

INDUSTRY RESTRAINT

Maintaining Quality and Consistency Across Regions

Ensuring quality and consistency in global R&D outsourcing is challenging due to varying regulatory standards across regions, especially in emerging markets. Companies rely on robust quality assurance and communication with authorities like the FDA and EMA while adapting to local regulations. In low-cost regions like Asia or Eastern Europe, strict oversight is crucial to maintaining data integrity and patient safety in multi-continent clinical trials.

SEGMENTATION INSIGHTS

INSIGHTS BY STAGE OF DEVELOPMENT

The global pharmaceutical R&D outsourcing market by stage of development is segmented into clinical and non-clinical. The clinical segment dominates and holds the largest market share. The growth is driven by the unique outsourcing needs of each development phase. Early stages like preclinical and Phase I focus on drug discovery, target validation, and toxicity testing, often handled by CROs and CDMOs to leverage their expertise and cost-efficient infrastructure. Companies like Covance, Charles River, and Syneos Health now offer end-to-end project management and patient recruitment to expedite timelines. Later phases, particularly Phases II and III, require advanced data management, global logistics, and diverse patient recruitment. To address these demands, CROs are adopting digital and decentralized trial models, including virtual trials powered by AI and robotic process automation, which streamline recruitment, enhance patient engagement, and reduce delays, as seen in partnerships like those between AstraZeneca, Bayer, and AI-focused tech companies.

By Stage Of Development

• Clinical
• Non-clinical

INSIGHTS BY PRODUCT TYPE

The global pharmaceutical R&D outsourcing market by product type is categorized into small molecules and biologics. The biologics segment shows significant growth, with the fastest-growing CAGR of 11.14%. The Biologics complex therapies, derived from living organisms, are a key focus in pharmaceutical R&D. Their development and manufacturing are increasingly outsourced to specialized CDMOs due to the high costs, time intensity, and advanced equipment required, which can be challenging for many biotech firms and pharmaceutical companies to handle internally. Partnering with CDMOs allows these firms to leverage advanced technologies and expertise, significantly reducing production costs and time to market.

By Product Type

• Small Molecules
• Biologics

INSIGHTS BY COMPANY SIZE

Based on the company size, the small & mid-sized companies segment accounted for the largest share of the global pharmaceutical R&D outsourcing market. Small and mid-sized companies are becoming key players in the pharmaceutical R&D outsourcing market. Faced with rising costs and the complexity of drug development, they increasingly rely on CROs for preclinical research, clinical trials, and regulatory support. This approach allows them to stay competitive and bring innovative therapies to market without the need for extensive in-house resources. The demand for CRO services is particularly strong in Europe and Asia-Pacific, where these companies benefit from partnerships to navigate regulatory challenges and reduce operational costs. Europe, with its skilled workforce and cost-effective trials, has emerged as a major hub for outsourced R&D.

By Company Size

• Small & Mid-sized Companies
• Large Companies

INSIGHTS BY THERAPY AREA

Based on the therapy area, the oncology segment holds the largest market share of over 30%. The oncology segment leads pharmaceutical R&D outsourcing, driven by the growing demand for innovative cancer treatments and efficient clinical trials. Accounting for about 70% of the global R&D pipeline, oncology sees significant competition and investment in early-stage research, particularly in personalized and cell-based therapies. Emerging biotech firms in North America and Europe are increasingly outsourcing preclinical and clinical trial services to CROs like IQVIA and PPD to reduce costs and speed up timelines. These CROs support complex oncology studies through platform and decentralized trials, improving patient recruitment and data management. The global demand for oncology outsourcing continues to grow, fueled by the rise in difficult-to-treat cancers and the expansion of specialized facilities, particularly in North America, Europe, and Asia-Pacific. North America remains the largest market due to its CRO concentration, while Asia-Pacific offers cost-effective clinical trials, especially for biologics and cell therapies, with firms like Novartis and Pfizer outsourcing extensively in the region.

By Therapy Area

• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Musculoskeletal Disorders
• Central Nervous System Disorders
• Gastrointestinal Disorders
• Others

GEOGRAPHICAL ANALYSIS

APAC shows prominent growth, with the fastest-growing CAGR of 11.91% in the global pharmaceutical R&D outsourcing market. The Asia-Pacific (APAC) region is growing rapidly, driven by cost efficiency, specialized expertise, and supportive government policies. Countries like China, India, and South Korea offer lower labor costs and advanced infrastructure, making them hubs for outsourced manufacturing and clinical trials. APAC is now the fastest-growing region in this market, fueled by the rising demand for biologics such as monoclonal antibodies and cell therapies, which require specialized capabilities. As R&D costs rise and patent expirations create pressure, many pharmaceutical companies are partnering with regional CROs to manage preclinical development and clinical trials more cost-effectively. Additionally, APAC is emerging as a key player in-process R&D, particularly in biologics and DMPK, where CROs provide deep expertise and scalable solutions.

By Geography

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• APAC
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • South Africa
  • UAE

COMPETITIVE LANDSCAPE

The global pharmaceutical R&D outsourcing market report consists of exclusive data on 44 vendors. Major players like Boehringer Ingelheim, Charles River Laboratories, ICON, IQVIA, Fortrea, Lonza, Medpace, Parexel International Corp, Samsung Biologics, Syneos Health, Thermo Fisher Scientific, and WuXi AppTec dominate the market. These companies offer end-to-end solutions, from drug discovery to clinical trials, providing efficiency and expertise that appeal to large pharmaceutical firms. As R&D grows more complex, outsourcing is shifting toward specialized services like gene and cell therapy research, biologics, and personalized medicine, driving significant investment and innovation. With stricter regulations in markets like the EU and China, companies are increasingly partnering with CROs that excel at navigating the evolving global regulatory landscape.

Key Vendors

• Boehringer Ingelheim
• Charles River Laboratories
• ICON
• IQVIA
• Fortrea
• Lonza
• Medpace
• Parexel International Corp
• Samsung Biologics
• Syneos Health
• Thermo Fisher Scientific
• WuXi AppTec

Other Prominent Vendors

• AbbVie
• ProtaGene
• Asymchem Laboratories
• Alcami
• Bavarian Nordic
• Catalent
• Curia Global
• ChemPartner
• Aixial Group
• Criterium
• Cromos Pharma
• Evotec
• Jubilant HollisterStier
• KBI Biopharma
• KCR S.A.
• Kemwell Biopharma
• Mesned Pharma Consult Center (MPCC)
• Midas Pharma
• Medelis
• Merck KGaA
• OCT Clinical
• Pharmaceutics International
• ProTrials Research
• Prometrika
• QPS
• Singota Solutions
• Sofpromed
• Sanofi S.A.
• Taros Chemicals
• Veristat
• Worldwide Clinical Trials
• Wacker Biotech

KEY QUESTIONS ANSWERED:

1. How large is the global pharmaceutical R&D outsourcing market?

2. Which product has the largest share of the global pharmaceutical R&D outsourcing market?

3. What are the latest trends in the global pharmaceutical R&D outsourcing market?

4. Who are the key players in the global pharmaceutical R&D outsourcing market?

5. Which shows the highest growth in the global pharmaceutical R&D outsourcing market?

TABLE OF CONTENTS

CHAPTER - 1: Pharmaceutical R&D Outsourcing Market Overview

• Executive Summary
• Key Findings

CHAPTER - 2: Pharmaceutical R&D Outsourcing Market

• GLOBAL: Projected Revenue of Pharmaceutical R&D Outsourcing Market (2020-2029; $ Billions)

CHAPTER - 3: Pharmaceutical R&D Outsourcing Market Prospects & Opportunities

• Pharmaceutical R&D Outsourcing Market Opportunities & Trends
• Pharmaceutical R&D Outsourcing Market Drivers
• Pharmaceutical R&D Outsourcing Market Constraints

CHAPTER - 4: Pharmaceutical R&D Outsourcing Market Segmentation Data

• GLOBAL: Projected Revenue by Stage of Development (2020-2029; $ Billions)
  • Clinical
  • Non-clinical
• GLOBAL: Projected Revenue by Product Type (2020-2029; $ Billions)
  • Small Molecules
  • Biologics
• GLOBAL: Projected Revenue by Company Size (2020-2029; $ Billions)
  • Small & Mid-Sized Companies
  • Large Companies
• GLOBAL: Projected Revenue by Therapy Area (2020-2029; $ Billions)
  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Musculoskeletal Disorders
  • Central Nervous System Disorders
  • Gastrointestinal Disorders
  • Others

CHAPTER - 5: Key Regions Overview

• North America: Projected Revenue of Pharmaceutical R&D Outsourcing Market (2020-2029; $ Billions)
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in the US
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Canada
• Europe: Projected Revenue of Pharmaceutical R&D Outsourcing Market (2020-2029; $ Billions)
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Germany
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in the UK
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in France
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Spain
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Italy
• APAC: Projected Revenue of Pharmaceutical R&D Outsourcing Market (2020-2029; $ Billions)
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in China
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Japan
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in India
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Australia
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in South Korea
• Latin America: Projected Revenue of Pharmaceutical R&D Outsourcing Market (2020-2029; $ Billions)
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Brazil
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Mexico
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Argentina
• Middle East & Africa: Projected Revenue of Pharmaceutical R&D Outsourcing Market (2020-2029; $ Billions)
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Turkey
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in Saudi Arabia
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in South Africa
  • Projected Revenue of Pharmaceutical R&D Outsourcing Market in UAE

CHAPTER - 6: Pharmaceutical R&D Outsourcing Market Industry Overview

• Pharmaceutical R&D Outsourcing Market - Competitive Landscape
• Pharmaceutical R&D Outsourcing Market- Key Vendor Profiles
• Pharmaceutical R&D Outsourcing Market- Other Prominent Vendors
• Pharmaceutical R&D Outsourcing Market - Key Strategic Recommendations

CHAPTER - 7: Appendix

• Research Methodology
• Abbreviations
• About Arizton